India Pharma Outlook Team | Wednesday, 26 November 2025
Eris Lifesciences announced that its board has sanctioned the purchase of the remaining 30 percent share in its subsidiary Swiss Parenterals.
The suggested transaction will take place as a share exchange, involving a preferential issuance of the company's shares to seller Naishadh Shah, thus positioning him as a shareholder and a key member of the company's senior management team with long-term alignment, as stated by the Mumbai-based firm
"On behalf of the shareholders of Eris, I am delighted to welcome Naishadh Shah to the community of Erisians. I am also happy to share that we propose to designate him as the Managing Director of Swiss Parenterals," Eris Lifesciences Chairman and Managing Director Amit Bakshi said.
FY27 is set to be a transformative year for the company's global operations, and Naishadh's ongoing leadership and guidance will be crucial for its expansion, he emphasized.
Also Read: CDSCO Mandates Licensing for All Medical Device Purchases
Eris Lifesciences shares were trading at Rs 1,665.20 each, down 0.99 percent on the BSE.
The company mainly concentrates on therapeutic areas related to chronic conditions and lifestyle factors, including diabetes, cardiovascular issues, and metabolic diseases, ensuring a robust and consistent market presence.
The company utilizes a branded-formulations business approach, which entails creating, producing, and promoting its own range of medicines instead of primarily depending on unbranded generics.
Throughout the years, Eris has grown into further therapeutic fields such as dermatology, women's health, neuroscience, nephrology, and nutrition, creating a diverse product range that includes medical tablets, syrups, capsules, injections, ointments, and other delivery methods.
